Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The FDA has approved Wyeth Pharmaceuticals' Protonix delayed-release oral suspension, a new addition to the Protonix family of prescription medications, for treatment of erosive gastroesophageal reflux disease.
Subscribe to our email newsletter
Protonix delayed-release oral suspension can be administered orally in applesauce or apple juice, or through a nasogastric tube. Protonix delayed-release oral suspension is indicated for the treatment and maintenance of healing of erosive esophagitis, with associated gastroesophageal reflux disease symptoms.
Protonix is contraindicated in patients with known hypersensitivity to any component of the formulation. Patients treated with proton pump inhibitors and warfarin concomitantly should be monitored for increases in INR and prothrombin time.
Richard Lynn, senior director, global medical affairs for Wyeth Pharmaceuticals, said: “The availability of Protonix for delayed-release oral suspension provides adult patients who cannot swallow tablets with an effective and convenient way to treat their erosive gastroesophageal reflux disease.”